
-
Madrigal Pharmaceuticals NasdaqGS:MDGL Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Location: Four Tower Bridge, West Conshohocken, PA, 19428, United States | Website: https://www.madrigalpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.27B
Cash
843.1M
Avg Qtr Burn
-98.83M
Short % of Float
32.85%
Insider Ownership
14.42%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezdiffra (Resmetirom) (MGL-3196) Details Non-alcoholic steatohepatitis , Liver disease | Approved Quarterly sales | |
Resmetirom (MGL-3196) Details Fatty liver disease, Liver disease | Phase 3 Data readout | |
Rezdiffra (Resmetirom) (MGL-3196) Details Liver disease, Cirrhosis | Phase 3 Data readout |